Sentences with phrase «hepatic cirrhosis»

Today it is used to treat dyspepsia, toxic liver and hepatic cirrhosis.

«About one - third of the fatal cases of hepatic cirrhosis are attributable to bacterial infections,» says Prof. Dr. Jonel Trebicka, from the Department of Internal Medicine in the University Hospital Bonn, who is participating in the study and has been studying liver cirrhosis for many years.

NASH promotes collagen deposition in the liver called hepatic fibrosis and can develop into hepatic cirrhosis.

Not exact matches

The disease is the consequence of obesity, diabetes, or excessive alcohol intake and can lead to non-alcoholic steatohepatitis (NASH), cirrhosis, liver cancer and even hepatic failure.

Hepatic encephalopathy occurs when the liver can not remove certain toxins and chemicals, such as ammonia, from the blood.1 These toxins and chemicals then build up and enter the brain.1 Hepatic encephalopathy is one of the major complications of cirrhosis (scarring of the liver), and a leading cause of hospital re-admission due to its recurrence, despite treatment.1 It can occur suddenly in people with acute liver failure, but is seen more often in those with chronic liver disease.1 Symptoms of hepatic encephalopathy include mild confusion, forgetfulness, poor concentration and personality or mood changes, but can progress to extreme anxiety, seizures, severe confusion, jumbled and slurred speech and slow movement.1 The first step in treatment is to identify and treat any factors that cause hepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care treHepatic encephalopathy occurs when the liver can not remove certain toxins and chemicals, such as ammonia, from the blood.1 These toxins and chemicals then build up and enter the brain.1 Hepatic encephalopathy is one of the major complications of cirrhosis (scarring of the liver), and a leading cause of hospital re-admission due to its recurrence, despite treatment.1 It can occur suddenly in people with acute liver failure, but is seen more often in those with chronic liver disease.1 Symptoms of hepatic encephalopathy include mild confusion, forgetfulness, poor concentration and personality or mood changes, but can progress to extreme anxiety, seizures, severe confusion, jumbled and slurred speech and slow movement.1 The first step in treatment is to identify and treat any factors that cause hepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care treHepatic encephalopathy is one of the major complications of cirrhosis (scarring of the liver), and a leading cause of hospital re-admission due to its recurrence, despite treatment.1 It can occur suddenly in people with acute liver failure, but is seen more often in those with chronic liver disease.1 Symptoms of hepatic encephalopathy include mild confusion, forgetfulness, poor concentration and personality or mood changes, but can progress to extreme anxiety, seizures, severe confusion, jumbled and slurred speech and slow movement.1 The first step in treatment is to identify and treat any factors that cause hepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care trehepatic encephalopathy include mild confusion, forgetfulness, poor concentration and personality or mood changes, but can progress to extreme anxiety, seizures, severe confusion, jumbled and slurred speech and slow movement.1 The first step in treatment is to identify and treat any factors that cause hepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care trehepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care trehepatic encephalopathy episode — lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above - mentioned standard of care treatment.

Researchers randomised 20 men with cirrhosis who experienced recurrent episodes of hepatic encephalopathy prior to the start of the study, to treatment with lactulose and rifaximin (standard of care treatment), or, broad spectrum antibiotics for five days plus a single fecal transplant from a healthy donor along with continuing the standard of care.

A single treatment using an optimized, targeted form of faecal microbiota transplantation (FMT) produces sustained clinical and cognitive improvements, according to the results of a long - term follow - up of patients with liver cirrhosis and hepatic encephalopathy (HE) who had participated in a short - term study.

14 April 2018, Paris, France: A single treatment using an optimized, targeted form of faecal microbiota transplantation (FMT) produces sustained clinical and cognitive improvements, according to the results of a long - term follow - up of patients with liver cirrhosis and hepatic encephalopathy (HE) who had participated in a short - term study.

Cirrhosis of the liver is a type of chronic liver damage most commonly caused by heavy alcohol use or hepatitis C. People with cirrhosis can develop a condition called hepatic encephalopathy (HE), which can have cognitiveCirrhosis of the liver is a type of chronic liver damage most commonly caused by heavy alcohol use or hepatitis C. People with cirrhosis can develop a condition called hepatic encephalopathy (HE), which can have cognitivecirrhosis can develop a condition called hepatic encephalopathy (HE), which can have cognitive effects.

The clove treatment was found to significantly reduce hepatic cell proliferation and processes involved in liver cirrhosis.

This can lead to an abnormal accumulation of excessive copper in the liver known as copper storage hepatopathy, leading to hepatic dysfunction and scarring (cirrhosis).

A breed predisposition to chronic hepatitis and hepatic fibrosis and cirrhosis also exists.

Chronic hepatitis in dogs, also called inflammatory canine hepatic disease, refers to a syndrome in which death of hepatic cells (hepatocellular necrosis) has occurred and is associated with a chronic inflammatory process which typically progresses to liver fibrosis (replacement of hepatic tissue with fibrous tissue) and cirrhosis (progressive derangement of the liver architecture and function).

This type of liver shunt is more commonly noted in dogs that have severe and chronic hepatic (liver) disease; especially those diseases involving a large population of hepatic tissues, hepatitis, cirrhosis and fibrosis.

A spokesperson for the pharmaceutical company said that the new labels will also warn of a contraindication for patients with Child - Pugh B cirrhosis, and will include a recommendation that medical professionals look for evidence of hepatic decompensation before prescribing Viekira Pak.